Sun Pharma announces research collaboration with Schrodinger

0 435

MUMBAI  : Schrödinger and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to accelerate the discovery of novel CNS therapeutics by leveraging Schrödinger’s advanced computational platform and SPARC’s extensive drug development expertise and insights in neurodegeneration.

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions that accelerate and increase the efficiency of drug discovery and materials design. Schrödinger has a growing pipeline of early stage assets and has co-founded leading biotech companies, including Nimbus Therapeutics and Morphic Therapeutic.

Schrödinger, will focus on lead discovery and optimization. SPARC, a clinical-stage company focused on improving patient care through innovation, will be responsible for compound synthesis and assays.

“This research collaboration is particularly exciting because neurodegeneration is an area where we urgently need more options for patients through novel approaches to drug discovery and development,”said Ramy Farid, Ph.D., president and CEO of Schrödinger. “SPARC has been working with leading academic researchers to explore pathways relevant to disorders of the central nervous system, and their insights are quite compelling. Teaming up will allow us to rapidly interrogate therapeutic compounds that target these pathways.”

Leave A Reply

Your email address will not be published.